BRINSUPRI (Brensocatib) Patent Expiration, LOE Window & CMS Spending

BRINSUPRI (Brensocatib) by Insmed: FDA Orange Book core substance LOE 2040-02-21, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $7,333 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorInsmed
FDA Application & PathwayN217673 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2040-02-21
Last Listed Patent or Exclusivity Date2040-02-21
Orange Book Patents (*PED Extensions)28 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($7,333 intro WAC)